Advance in research of imidazoles as anti-tumor agents

Chinese Journal of New Drugs

Volumn 18, Issue 7, 2009, Pages 598-608

  Cai, Jia Li ^a   Li, Shuo ^a   Zhou, Cheng He ^a   Gan, Lin Ling ^a   Wu, Jun ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Anti tumor; Benzimidazole; Farnesyl transferase inhibitor; Imidazole; Nitroimidazole; Radiosensitizer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME P450 INHIBITOR; DNA TOPOISOMERASE INHIBITOR; IMIDAZOLE DERIVATIVE; NITROIMIDAZOLE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT;

ARTICLE; CELL STRAIN U937; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; HELA CELL; HUMAN; STRUCTURE ACTIVITY RELATION;

EID: 77649235517     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. YOON J, KIM SK, SINGH NJ, et al. Imidazolium receptors for the recognition of anions [J]. Chem Soc Rev, 2006, 35 (4): 355-360.
2. JIANG HY, ZHOU CH, LUO K, et al. Chiral imidazole metalloenzyme models: Synthesis and enantioselective hydrolysis for α-amino acid esters [J]. J Mol Cat A: Chem, 2006,260 (1-2): 288-294.
3. 3 receptor ligand [J]. Chin Pharm J, 2007,42(6): 404-409.
4. TANABE K, KOJIMA R, HATTA H, et al. Propargylic sulfones possessing a 2-nitroimidazole function: novel hypoxic-cell radio-sensitizers with intracellular non-protein thiol depletion ability [J]. Bioorg Med Chem Lett, 2004,14 (10): 2633-2635.
5. MILLER TJ, SCHNEIDER RJ, MILLER JA, et al. Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3[J]. Neurotoxicology, 2006,27 (1): 44-59.
6. PAPADOPOULOU MV, ROSENZWEIG HS, BLOOMER WD. Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin[J]. Bioorg Med Chem Lett, 2004,14(6): 1519-1522.
7. JIN CZ, NAGASAWA H, SHIMAMURA M, et al. Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylearbamoyl-2-nitroimidazole hypoxic cell radiosensitizers[J]. Bioorg Med Chem, 2004,12(18): 4917-4927.
8. LIN NH, WANG L, WANG XL, et al. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyl transferase inhibitor [J]. Bioorg Med Chem Lett, 2004,14 (20): 5057-5062.
9. LI Q, WOODS KW, WANG WB, et al. Design, synthesis and activity of achiral analogs of 2 -quinolones and indoles as non-thiol farnesyl transferase inhibitors[J]. Bioorg Med Chem Lett, 2005, 15(8): 2033-2039.
10. GWALTNEY SL 2ND, O'CONNOR SJ, NELSON LT, et al. Aryl tetrahydropyridine inhibitors of farnesyl transferase: bioavailable analogues with improved cellular potency[J]. Bioorg Med Chem Lett, 2003, 13(7): 1363-1366.
11. TONG YS, LIN NH, WANG L, et al. Discovery of potent imidazole and cyanophenyl containing farnesyl transferase inhibitors with improved oral bioavailability[J]. Bioorg Med Chem Lett, 2003, 13(9): 1571-1574.
12. ANGIBAUD P, MEBELLEC L, MEYER C, et al. Impact on farnesyl transferase inhibition of 4-chlorophenyl moietyreplacement in the Zarnestra series [J]. Eur J Med Chem, 2007, 42 (5): 702-714.
13. LI Q, CLAIBORNE A, LI T M, et al. Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyl transferase inhibitors[J]. Bioorg Med Chem Lett, 2004,14(21): 5367-5370.
14. CURTIN ML, FLORJANCIC AS, COHEN J, et al. Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyl transferase [J]. Bioorg Med Chem Lett, 2003, 13 (7): 1367-1371.
15. CHRISTELLE P, SAMIR Y, CATHERINE F, et al. Synthesis and biological evaluation of 4-imidazolylflavans as nonsteroidal aromatase inhibitors[J]. Bioorg Chem, 2004,32(6): 494-503.
16. HACKETT JC, KIM YW, SU B, et al. Synthesis and characterization of azole isoflavone inhibitors of aromatase [J]. Bioorg Hed Chem Lett, 2005 13 (2): 4063-4070.
17. BRUNO RD, NJAR VCO. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development[J]. Bioorg Med Chem, 2007, 15(15): 5047-5060.
18. MATSUANAGA N, KAKU T, ITOH F, et al. C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors[J]. Bioorg Med Chem, 2004,12 (9): 2251-2273.
19. MATSUNAGA N, KAKU T, OJIDA A, et al. C17,20-lyase inhibitors. Part 2: Design, synthesis and structure-activity relationships of (2-naphthylmethyl) -1H-imidazoles as novel C 17,20 -lyase inhibitors[J]. Bioorg Med Chem, 2004, 12(16):4313-4136.
20. RAY S, CHATURVEDI D. Application of organic carbamates in drug design. Part 1: anticancer agents-recent reports[J]. Drugs Fut, 2004,29(4):343-357.
21. HORI A, IMAEDA Y, KUBO KJ, et al. Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo [J]. Cancer Lett, 2002, 183 (1): 53-60.
22. KAMAL A, RAMULU P, SRINIVAS O, et al. Synthesis of C8-linked pyrrolo [2, 1-c] [1,4] benzodiazepine-benzimidazole conjugates with remarkable DNA-binding affinity[J]. Bioorg Med Chem Lett, 2004,14(18): 4791-4794.
23. PINAR A, YURDAKUL P, YILDIZ I, et al. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors[J]. Biochem Biophys Res Commun, 2004,317(2): 670-674.
24. HUANG S, LIN R H, YU Y, et al. Synthesis of 3-(1H-benzimidazol-2-yl) -5-isoquinolin-4-yl pyrazolo [1,2-b] pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor[J]. Bioorg Med Chem Lett, 2007,17(5): 1243-1245.
25. FABIO B, SILVIA C, SUSANNA M, et al. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin[J]. Bioorg Med Chem Lett, 2006,16(22): 5757-5762.
26. ZHOU CH, HASSENER A. Synthesis and anticancer activity of novel chiral D-glucose derived bis-benzinvidazoles and analogues [J]. Carbohydr Res, 2001,333(4): 313-326.
27. WHITE AW, CURTIN NJ, EASTMAN BW, et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors [J]. Bioorg Med Chem Lett, 2004,14(10): 2433-2437.
28. RAY S, CHATURVED D. Application of organic carbamates in drug design. Part 1: anticancer agents-recent reports [J]. Drugs Fut, 2004,29(4): 343-357.
29. CHEN ZF, WANG XY, ZHU YG, et al. Selective guanosine binding and cytotoxicity of a benzimidazole derived dinickel complex[J]. J Inorg Biochem, 2007,101(11-12): 1894-1902.
30. GREEN JR. Zoledronic acid: pharmacologic profile of a potent bisphosphonate[J]. J Org Chem, 2005, 690(10): 2439-2448.